Investors Review: Delcath Systems, Inc. (NASDAQ:DCTH), Genworth Financial Inc (NYSE:GNW), Zogenix, Inc. (NASDAQ:ZGNX)

Dallas, TX -- (SBWIRE) -- 03/12/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Delcath Systems, Inc. (NASDAQ:DCTH) shares climbed 8.67% to $2.13. The company, on Feb. 27, announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the Company's pending New Drug Application (NDA) for a drug/device combination product with the proposed trade name Melblez KitTM (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System.

Additionally, the company announced that it will host a conference call and webcast on Wednesday, March 13, 2013 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year 2012 ended December 31, 2012, and provide an update on recent corporate progress.

Is DCTH a Strong Buy After The Recent Gain? Let’s Find out Here

Genworth Financial Inc (NYSE:GNW) shares climbed 6.71% to $10.50 after GNW’s stock was upgraded by equities research analysts at Scotiabank from an “underperform” rating to a “sector outperform” rating in a research note issued to investors this month.

Additionally, the company, on Mar. 6, said it is suspending sales of coverage to individuals in California as it works to get regulatory approval for a new product that raises prices and reduces benefits for policyholders.

Is GNW a Strong Buying Opportunity After The Recent Slump? Find out Here

Zogenix, Inc. (NASDAQ:ZGNX) stock climbed 6.18% to $1.89. Research analysts at Brinson Patrick assumed coverage on shares of ZGNX in a report released on Mar. 5. The firm set an “outperform” rating and a $5.00 price target on the stock.

The company, on Feb. 26, announced that it has been informed by the U.S. Food and Drug Administration (FDA) that Zogenix is unlikely to receive an action letter for its New Drug Application (NDA) for ZohydroTM ER (hydrocodone bitartrate extended-release capsules) by the Prescription Drug User Fee Act (PDUFA) goal date of March 1, 2013.

Should Investors Consider ZGNX After The Recent price Action? Get Free Trend Analysis Here

About Marketbuzzreport.com
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com

Disclaimer
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.